We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.


'A most wonderful Christmas present': HSE to reimburse cost of new cystic fibrosis treatment

About 1,200 children and adults have Cystic Fibrosis in Ireland.

THE FIRST DRUG to treat the underlying cause of cystic fibrosis (CF) for around 80% of those with the disease in Ireland has been approved by the HSE. 

The HSE today announced that it has expanded its reimbursement agreement with Vertex Pharmaceuticals. 

As a result, all patients in Ireland with CF who are aged 12 and over and who have at least one copy of the F508del gene mutation will get access to the drug therapy, Trikafta, once it is approved by the European Medicines Agency. 

This is expected to happen in the first quarter of 2020. 

CF, an inherited chronic disease that primarily affects the lungs and digestive system, can greatly impact the lifespan of those with the debilitating condition.

About 1,200 children and adults have CF in Ireland, which has more cases of it per head of population than any other country.

Trikafta was approved in the US on 21 October 2018, some five months ahead of schedule.

Cystic Fibrosis Ireland CEO Philip Watt has said this development is “a most wonderful Christmas present for all those with cystic fibrosis in Ireland”. 

“The drug therapy Trikafta is what many scientists and patients have been waiting on since the basic genetic cause of CF became understood in 1989,” Watt said. 

He added that it is likely that most of those on existing CF drugs such as Orkambi will transfer over to Trikafta “depending on the advice of their clinician”. 

Health Minister Simon Harris also welcomed the HSE’s announcement. 

“This is incredible news for CF patients and their families and is another important step on the road to improving outcomes for cystic fibrosis patients,” Harris said. 

“This is another milestone and I congratulate everyone who worked to achieve this.” 

Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.

Your Voice
Readers Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel